Clinical Trial Update: MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Monalizumab in combination with durvalumab for small cell lung cancer is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Limited-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Monalizumab (monalizumab)

Snippet

Sponsor: Hirva Mamdani | Conditions: Small Cell Lung Cancer, SCLC | Phase 2 | Status: SUSPENDED